Editorial
The model-based approach to clinical studies in particle radiotherapy – A new concept in evidence based radiation oncology?

https://doi.org/10.1016/j.radonc.2013.06.031Get rights and content

References (25)

Cited by (19)

  • Optimal Allocation of Proton Therapy Slots in Combined Proton-Photon Radiation Therapy

    2021, International Journal of Radiation Oncology Biology Physics
    Citation Excerpt :

    Consequently, only a small percentage of patients with an indication for radiation therapy are treated with protons,7 and not all patients who may benefit from proton therapy have access to it.8 Strategies for selecting patients for proton therapy vary among institutions, countries, and health care systems.9-15 In most countries, several treatments are considered standard indications for proton therapy, including pediatric patients and tumors in the proximity of the base of the skull or the spinal cord (eg, chordoma and chondrosarcoma).9,15,16

  • Clinical practice vs. state-of-the-art research and future visions: Report on the 4D treatment planning workshop for particle therapy – Edition 2018 and 2019

    2021, Physica Medica
    Citation Excerpt :

    Although several RCTs are currently ongoing around the world, the necessity of long-term follow up of tumor progression and side effects limits the feasibility of their use in rapid technological evolution of 4D proton therapy. The model-based approach is an alternative method of defining which patients would receive the greatest clinical gain from selected therapy [23–24]. It is based on comparative evaluations of photon and proton plans with regard to radiation toxicity predicted by normal tissue complication probability (NTCP) models.

  • Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy

    2019, Trends in Cancer
    Citation Excerpt :

    A mathematical model suggested that this new treatment technique could decrease overall radiation-induced toxicity to feathered OARs or be used to increase the total dose to the tumor if needed without additional OAR toxicity compared with standard RT plans. With the same aim of reducing OAR toxicity, a NTCP-based approach has been recently proposed to select patients that would benefit from proton therapy rather than photon therapy [31,32]. Although this method has already been adopted by the Dutch Health Council and the Dutch Health Care Insurance Board, efforts are still needed to collect clinical radiobiology data to include routine morbidity assessments and further evaluation of the NTCP thresholds in the selection criteria and to find optimal models that balance data fit and predictability [33].

  • Union of light ion therapy centers in Europe (ULICE EC FP7) – Objectives and achievements of joint research activities

    2018, Radiotherapy and Oncology
    Citation Excerpt :

    Currently it is still subject of investigation on which criteria an attending physician should base a final decision regarding the treatment modality for an individual patient. One practical solution is a direct comparison of patient specific dose distributions to discriminate between treatment options [48,49]. This may also include the application of available state-of-the-art tumor control probability and normal tissue complication probability models [50,51].

  • “Radiobiology of Proton Therapy”: Results of an international expert workshop

    2018, Radiotherapy and Oncology
    Citation Excerpt :

    It does, however, pose challenges in terms of the required accuracy of the underlying models [81,82]. Secondly, development and validation of thresholds for NTCP reduction is critical for selection and can introduce tremendous heterogeneity in clinical trials [83]. There are various clinical situations in which patients would benefit from proton therapy and where dose planning studies suggest a potential for improved outcome [84].

View all citing articles on Scopus
View full text